Each vial contains 5mg of highly pure GHRP-2 in lyophilized form.
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide classified as a growth hormone secretagogue, primarily studied for its ability to stimulate the release of endogenous growth hormone through activation of the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor. It has been widely investigated in research involving growth hormone physiology, metabolism, body composition, and endocrine regulation.
By binding to GHSR-1a receptors in the pituitary gland and hypothalamus, GHRP-2 promotes pulsatile secretion of growth hormone while also influencing the release of insulin-like growth factor-1 (IGF-1) through downstream endocrine signaling. In preclinical and clinical research, these mechanisms have been associated with enhanced protein synthesis, improved nitrogen retention, increased lean tissue development, and changes in energy metabolism under controlled experimental conditions.
Beyond its effects on growth hormone secretion, GHRP-2 has been studied for its influence on appetite regulation, gastrointestinal motility, and tissue repair. Activation of the ghrelin receptor has been shown to affect hunger signaling, gastric emptying, and cellular recovery pathways, making GHRP-2 a valuable research tool across multiple areas of endocrinology and metabolic science.
Unlike direct growth hormone administration, GHRP-2 stimulates the body’s natural pulsatile release of growth hormone, preserving physiological feedback mechanisms while producing a transient increase in circulating hormone levels. This receptor-mediated mechanism has made it one of the most extensively studied growth hormone secretagogues in experimental research.
GHRP-2 remains an investigational research peptide intended exclusively for laboratory and scientific research. It has not been approved for therapeutic use in humans, and its safety and efficacy continue to be evaluated through ongoing preclinical and clinical studies.
